Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.

Ms. Sweeny has served as Chief Commercial Officer of KalVista Pharmaceuticals since July 2023. Prior to this, she served as the Chief Commercial Officer of Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, from August 2020 to April 2023. She served as Vice President, Franchise Head, Rare Diseases of Takeda Pharmaceutical Co. Ltd., or Takeda, a biopharmaceutical company, from February 2019 to July 2020. Prior to Takeda, Ms. Sweeny served in several roles at Shire plc, a biopharmaceutical company acquired by Takeda, from August 2010 to January 2019, including Vice President, Head of US Marketing from September 2017 to January 2019 and Vice President, Global Product Strategy Lead from December 2016 to August 2017. Prior to joining Shire, Ms. Sweeny served in commercial positions of increasing responsibility at AMAG Pharmaceuticals, Inc. and Sanofi Genzyme Corporation. Ms. Sweeny received her B.S. in marketing from Boston College.

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.

Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Ms. Sweeny has served as Chief Commercial Officer of KalVista Pharmaceuticals since July 2023. Prior to this, she served as the Chief Commercial Officer of Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, from August 2020 to April 2023. She served as Vice President, Franchise Head, Rare Diseases of Takeda Pharmaceutical Co. Ltd., or Takeda, a biopharmaceutical company, from February 2019 to July 2020. Prior to Takeda, Ms. Sweeny served in several roles at Shire plc, a biopharmaceutical company acquired by Takeda, from August 2010 to January 2019, including Vice President, Head of US Marketing from September 2017 to January 2019 and Vice President, Global Product Strategy Lead from December 2016 to August 2017. Prior to joining Shire, Ms. Sweeny served in commercial positions of increasing responsibility at AMAG Pharmaceuticals, Inc. and Sanofi Genzyme Corporation. Ms. Sweeny received her B.S. in marketing from Boston College.

Ms. Talukdar has served as Senior Vice President, Head of Investor Relations at Moderna Inc. since April 2019. She brings over 20 years of experience in investor relations, healthcare investments, and financial strategy. Before joining Moderna, Ms. Talukdar was a Senior Portfolio Manager at Abu Dhabi Investment Authority (ADIA), overseeing global healthcare investments, and previously served as a Partner and Healthcare Equity Analyst at Lord Abbett & Co. She also held investment roles at MFS Investment Management and State Street Global Advisors. Ms. Talukdar received her B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.

Mr. Anderson has more than 30 years of biopharmaceutical sector experience, primarily focused in financial management. He was CFO at such notable companies as BioMarin and Dow Pharmaceutical Sciences, Inc. (now a wholly owned subsidiary of Valeant Pharmaceuticals International), and was a board member and chair of the audit committee for Raptor Pharmaceutical Corp. (now a wholly owned subsidiary of Horizon Pharma plc).

Ms. Sweeny has served as Chief Commercial Officer of KalVista Pharmaceuticals since July 2023. Prior to this, she served as the Chief Commercial Officer of Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, from August 2020 to April 2023. She served as Vice President, Franchise Head, Rare Diseases of Takeda Pharmaceutical Co. Ltd., or Takeda, a biopharmaceutical company, from February 2019 to July 2020. Prior to Takeda, Ms. Sweeny served in several roles at Shire plc, a biopharmaceutical company acquired by Takeda, from August 2010 to January 2019, including Vice President, Head of US Marketing from September 2017 to January 2019 and Vice President, Global Product Strategy Lead from December 2016 to August 2017. Prior to joining Shire, Ms. Sweeny served in commercial positions of increasing responsibility at AMAG Pharmaceuticals, Inc. and Sanofi Genzyme Corporation. Ms. Sweeny received her B.S. in marketing from Boston College.